Why Commercial Insurance Premiums Are Rising for Biotech Firms in 2026 and What You Can Do About It

The biotechnology industry continues to be one of the most innovative sectors in the global economy. From groundbreaking therapies and medical devices to advanced diagnostics and life science research, biotech companies are pushing the boundaries of science. Unfortunately, they are also facing rising commercial insurance costs in 2026.
​
Many biotech executives are asking the same question: Why are premiums increasing, and what can we do to control costs?

As a risk management and insurance professional who works with life science and biotech firms, I believe understanding the causes behind these increases is the first step toward managing them effectively.

Why Are Biotech Insurance Premiums Increasing?
Several factors are driving higher insurance costs across the biotech sector.

Increased Product Liability Exposure
As biotech companies move products from research and development into clinical trials and commercialization, liability risks increase significantly.
Insurance carriers are seeing larger claims involving:

• Medical devices
• Pharmaceutical products
• Gene therapies
• Diagnostic technologies
• Clinical trial participants

Even a single adverse event can result in substantial legal expenses, settlements, and reputational damage. As claim severity increases, insurers adjust premiums accordingly.

Rising Litigation Costs
Lawsuits are becoming more expensive across all industries, and biotech is no exception.
Higher attorney fees, larger jury verdicts, and increasing settlement amounts have caused insurance companies to reevaluate pricing models. Carriers are building these rising costs into their premiums to maintain profitability.

Growing Cyber Threats
Biotech firms possess highly valuable information, including:

• Proprietary research
• Clinical trial data
• Intellectual property
• Patient information
• Regulatory filings

Cybercriminals recognize the value of this data. Ransomware attacks and data breaches targeting life science organizations continue to increase, resulting in higher cyber liability insurance costs.

Regulatory Pressure
Regulatory agencies continue to expand oversight and compliance requirements. Any regulatory action, investigation, or compliance failure can lead to significant defense costs and financial loss.
Insurers are carefully evaluating regulatory exposure when underwriting biotech companies, particularly those involved in clinical trials, manufacturing, and international operations.

Reinsurance Market Challenges
Insurance companies purchase their own insurance through the reinsurance market. Global catastrophe losses, economic uncertainty, and large liability claims have increased reinsurance costs, which are often passed down to policyholders through higher premiums.

What Biotech Companies Can Do to Control Insurance Costs
While market conditions may be challenging, there are several steps biotech firms can take to improve their risk profile and potentially reduce insurance costs.

Strengthen Risk Management Programs
Insurance carriers reward organizations that actively manage risk.
Focus on:

• Formal safety procedures
• Clinical trial oversight
• Documentation and quality control
• Employee training
• Incident reporting processes

Companies with strong risk management practices are often viewed more favorably during underwriting.

Invest in Cybersecurity
Cyber liability insurers are paying close attention to cybersecurity controls.
Key improvements include:

• Multi factor authentication
• Endpoint detection and monitoring
• Employee cybersecurity training
• Data backup procedures
• Incident response planning

Better cyber controls can improve insurability and may help reduce premiums.

Review Insurance Limits Carefully
Many biotech firms carry outdated limits that may not reflect their current operations. Others may purchase limits that are either insufficient or unnecessarily high.
An annual insurance review can help align coverage with actual exposures while eliminating inefficiencies.

Improve Contractual Risk Transfer
Contracts with suppliers, research partners, manufacturers, and vendors should clearly define responsibilities and indemnification obligations.
Proper risk transfer can reduce exposure and improve how underwriters evaluate your business.

Work with a Specialized Insurance Advisor
Biotech is not a standard industry. Companies need advisors who understand clinical trials, intellectual property concerns, regulatory challenges, product liability exposures, and life science operations.
A specialist can help negotiate with carriers, identify coverage gaps, and present your company in the strongest possible light during underwriting.

The Importance of Looking Beyond Price
Many biotech firms respond to rising premiums by shopping for the lowest cost policy. While this may reduce short term expenses, it can create significant coverage gaps.
The cheapest policy may exclude critical exposures such as:

• Clinical trials
• Product liability
• Regulatory investigations
• Intellectual property related claims
• Cyber incidents

The goal should not be finding the cheapest insurance. The goal should be finding the best value and protection for your specific risk profile.

How Strive Insurance Group Can Help
At Strive Insurance Group, we understand the unique challenges facing biotechnology and life science companies. We work closely with clients to identify exposures, strengthen risk management practices, and build insurance programs designed to support innovation and growth.
Our team helps biotech firms:

• Evaluate emerging risks
• Structure comprehensive insurance programs
• Improve underwriting outcomes
• Control long term insurance costs
• Protect investors, intellectual property, and operations

Insurance premiums for biotech companies are likely to remain under pressure throughout 2026 due to rising litigation, cyber threats, regulatory complexity, and product liability exposures. However, companies that proactively manage risk can position themselves for better pricing, stronger coverage, and greater long term stability.
The best strategy is not simply reducing premiums. It is reducing risk.
If your biotech company has not reviewed its insurance and risk management program recently, now is the time.

Contact Strive Insurance Group today to learn how we can help your biotech organization manage risk, strengthen protection, and navigate the evolving insurance market with confidence.